Hepcidin-25, Mean Corpuscular Volume, and Ferritin as Predictors of Response to Oral Iron Supplementation in Hemodialysis Patients

Nutrients

Volumn 7, Issue 1, 2015, Pages 103-118

  Takasawa, Kazuya ^a   Takaeda, Chikako ^a   Maeda, Teiryo ^b   Ueda, Norishi ^a  

^a Public Central Hospital of Matto Ishikawa   (Japan)

^b Biomarker Society   (Japan)

Author keywords

Anemia; ferritin; Hemodialysis; Hepcidin; Iron; Mean corpuscular volume

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; FERROUS FUMARATE; HEMOGLOBIN; HEPCIDIN; HUMAN SERUM ALBUMIN; IRON; PARATHYROID HORMONE; PHOSPHORUS; TRANSFERRIN; BIOLOGICAL MARKER; ERYTHROPOIETIN; FERROUS ION; IRON INTAKE;

ADULT; AGED; ARTICLE; BODY MASS; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY ARTERIOVENOUS FISTULA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ADMINISTRATION AND DOSAGE; ANEMIA, IRON-DEFICIENCY; BLOOD; IRON INTAKE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; ERYTHROCYTE INDICES; ERYTHROPOIETIN; FEMALE; FERRITINS; FERROUS COMPOUNDS; HEMOGLOBINS; HEPCIDINS; HUMANS; IRON, DIETARY; LINEAR MODELS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84920101236     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7010103     Document Type: Article

References (44)

1. Albaramki, J.; Hodson, E.M.; Craig, J.C.; Webster, A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 2012, 1, CD007857, doi:10.1002/14651858.CD007857.pub2.
2. Adhikary, L.; Acharya, S. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. JNMA J. Nepal Med. Assoc. 2011, 51, 133–136.
3. Liles, A.M. Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease. Am. J. Health Syst. Pharm. 2012, 69, 1206–1211.
4. Lenga, I.; Lok, C.; Marticorena, R.; Hunter, J.; Dacouris, N.; Goldstein, M. Role of oral iron in the management of long-term hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2007, 2, 688–693.
5. Tsuchida, A.; Paudyal, B.; Paudyal, P.; Ishii, Y.; Hiromura, K.; Nojima, Y.; Komai, M. Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate. Exp. Ther. Med. 2010, 1, 777–781.
6. Hastka, J.; Lasserre, J.J.; Schwarzbeck, A.; Reiter, A.; Hehlmann, R. Laboratory tests of iron status: Correlation or common sense? Clin. Chem. 1996, 42, 718–724.
7. Johnson-Wimbley, T.D.; Graham, D.Y. Diagnosis and management of iron deficiency anemia in the 21st century. Ther. Adv. Gastroenterol. 2011, 4, 177–184.
8. Pasricha, S.R.; Flecknoe-Brown, S.C.; Allen, K.J.; Gibson, P.R.; McMahon, L.P.; Olynyk, J.K.; Roger, S.D.; Savoia, H.F.; Tampi, R.; Thomson, A.R.; et al. Diagnosis and management of iron deficiency anaemia: A clinical update. Med. J. Aust. 2010, 193, 525–532.
9. Iolascon, A.; de Falco, l.; Beaumont, C. Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica 2009, 94, 395–408.
10. Ganz, T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117, 4425–4433.
11. Mercadel, L.; Metzger, M.; Haymann, J.P.; Thervet, E.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Houillier, P.; Froissart, M.; Stengel, B.; et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 2014, 9, e99781, doi:10.1371/ journal.pone.0099781.
12. Malyszko, J.; Malyszko, J.S.; Mysliwiec, M. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy. Kidney Blood Press. Res. 2009, 32, 235–238.
13. Tessitore, N.; Girelli, D.; Campostrini, N.; Bedogna, V.; Pietro Solero, G.; Castagna, A.; Melilli, E.; Mantovani, W.; de Matteis, G.; Olivieri, O.; et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol. Dial. Transplant. 2010, 25, 3996–4002.
14. Kato, A.; Tsuji, T.; Luo, J.; Sakao, Y.; Yasuda, H.; Hishida, A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am. J. Nephrol. 2008, 28, 115–121.
15. Kuragano, T.; Shimonaka, Y.; Kida, A.; Furuta, M.; Nanami, M.; Otaki, Y.; Hasuike, Y.; Nonoguchi, H. Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation. Am. J. Nephrol. 2010, 31, 534–540.
16. Van der Weerd, N.C.; Grooteman, M.P.; Bots, M.L.; van den Dorpel, M.A.; den Hoedt, C.H.; Mazairac, A.H.; Nubé, M.J.; Penne, E.L.; Gaillard, C.A.; Wetzels, J.F.; et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012, 7, e39783, doi:10.1371/journal.pone.0039783.
17. Uehata, T.; Tomosugi, N.; Shoji, T.; Sakaguchi, Y.; Suzuki, A.; Kaneko, T.; Okada, N.; Yamamoto, R.; Nagasawa, Y.; Kato, K.; et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: A cross-sectional study. Nephrol. Dial. Transplant. 2012, 27, 1076–1083.
18. Peters, H.P.; Laarakkers, C.M.; Swinkels, D.W.; Wetzels, J.F. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol. Dial. Transplant. 2010, 25, 848–853.
19. Takasawa, K.; Tomosugi, N.; Takaeda, C.; Maeda, T.; Ueda, N. Regulation of hepcidin-25 by short-and long-acting rhEPO may be dependent on ferritin and predict the response to rhEPO in hemodialysis patients. Nephron Extra 2014, 4, 55–63.
20. Thomas, C.; Kobold, U.; Balan, S.; Roeddiger, R.; Thomas, L. Serum hepcidin-25 may replace the ferritin index in the Thomas plot in assessing iron status in anemic patients. Int. J. Lab. Hematol. 2011, 33, 187–193.
21. Bregman, D.B.; Morris, D.; Koch, T.A.; He, A.; Goodnough, L.T. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J. Hematol. 2013, 88, 97–101.
22. Chand, S.; Ward, D.G.; Ng, Z.Y.; Hodson, J.; Kirby, H.; Steele, P.; Rooplal, I.; Bantugon, F.; Iqbal, T.; Tselepis, C.; et al. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J. Nephrol. 2014, doi:10.1007/s40620-014-0083-y.
23. Chen, Y.C.; Hung, S.C.; Tarng, D.C. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am. J. Kidney Dis. 2006, 47, 1036–1044.
24. Zlotkin, S.; Arthur, P.; Antwi, K.Y.; Yeung, G. Treatment of anemia with microencapsulated ferrous fumarate plus ascorbic acid supplied as sprinkles to complementary (weaning) foods. Am. J. Clin. Nutr. 2001, 74, 791–795.
25. DeLong, E.R.; DeLong, D.M.; Clarke-Pearson, D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988, 44, 837–845.
26. Zimmermann, J.; Herrlinger, S.; Pruy, A.; Metzger, T.; Wanner, C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999, 55, 648–658.
27. Peters, H.P.; Rumjon, A.; Bansal, S.S.; Laarakkers, C.M.; van den Brand, J.A.; Sarafidis, P.; Musto, R.; Malyszko, J.; Swinkels, D.W.; Wetzels, J.F.; et al. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol. Dial. Transplant. 2012, 27, 3923–3929.
28. Ford, B.A.; Eby, C.S.; Scott, M.G.; Coyne, D.W. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010, 78, 769–773.
29. Macdougall, I.C.; Malyszko, J.; Hider, R.C.; Bansal, S.S. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 5, 1681–1689.
30. Hsu, S.P.; Chiang, C.K.; Chien, C.T.; Hung, K.Y. Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purif. 2006, 24, 311–316.
31. Nakanishi, T.; Kuragano, T.; Kaibe, S.; Nagasawa, Y.; Hasuike, Y. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin. Exp. Nephrol. 2012, 16, 819–826.
32. Goldwasser, P.; Koutelos, T.; Abraham, S.; Avram, M.M. Serum ferritin, hematocrit and mean corpuscular volume in hemodialysis. Nephron 1994, 67, 30–35.
33. Lynn, K.L.; Mitchell, T.R.; Shepperd, J. Red cell indices and iron stores in patients undergoing haemodialysis. Br. Med. J. (Clin. Res. Ed.) 1981, 282, 2096, doi:10.2307/29502570.
34. Gokal, R.; Weatherall, D.J.; Bunch, C. Iron induced increase in red cell size in haemodialysis patients. Q. J. Med. 1979, 48, 393–401.
35. Nuwayri-Salti, N.; Jabre, F.; Daouk, M.; Sa’ab, G.; Salem, Z. Hematologic parameters and iron stores in patients on hemodialysis for chronic renal failure. Clin. Nephrol. 1992, 38, 101–104.
36. Moreb, J.; Popovtzer, M.M.; Friedlaender, M.M.; Konijn, A.M.; Hershko, C. Evaluation of iron status in patients on chronic hemodialysis: Relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin. Nephron 1983, 35, 196–200.
37. Markowitz, G.S.; Kahn, G.A.; Feingold, R.E.; Coco, M.; Lynn, R.I. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin. Nephrol. 1997, 48, 34–40.
38. Majoni, S.W.; Ellis, J.A.; Hall, H.; Abeyaratne, A.; Lawton, P.D. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia. Hemodial. Int. 2014, doi:10.1111/hdi.12173.
39. Zimmermann, M.B.; Troesch, B.; Biebinger, R.; Egli, I.; Zeder, C.; Hurrell, R.F. Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidin. Am. J. Clin. Nutr. 2009, 90, 1280–1287.
40. Pasricha, S.R.; Atkinson, S.H.; Armitage, A.E.; Khandwala, S.; Veenemans, J.; Cox, S.E.; Eddowes, L.A.; Hayes, T.; Doherty, C.P.; Demir, A.Y.; et al. Expression of the iron hormone hepcidin distinguishes different types of anemia in African children. Sci. Transl. Med. 2014, 6, 235re3, doi:10.1126/scitranslmed.3008249.
41. Singh, A.K.; Coyne, D.W.; Shapiro, W.; Rizkala, A.R.; the DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007, 71, 1163–1171.
42. Wright, C.M.; Kelly, J.; Trail, A.; Parkinson, K.N.; Summerfield, G. The diagnosis of borderline iron deficiency: Results of a therapeutic trial. Arch. Dis. Child. 2004, 89, 1028–1031.
43. Vreugdenhil, G.; Baltus, J.A.; van Eijk, H.G.; Swaak, A.J. Prediction and evaluation of the effect of iron treatment in anaemic RA patients. Clin. Rheumatol. 1989, 8, 352–362.
44. Macdougall, I.C. Strategies for iron supplementation: Oral versus intravenous. Kidney Int. Suppl. 1999, 69, S61–S66.